MRK vs PHAT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
PHAT presents a classic high-growth biotechnology profile, anchored by a stable Piotroski F-Score of 4/9 and an impressive 94.10% YoY revenue growth. While the company currently operates with deeply negative profit margins (-126.35%) and negative book value, the Forward P/E of 8.17 is exceptionally attractive compared to the healthcare sector average of 88.62. Strong analyst conviction with a target price of $23.70 and a consistent track record of earnings beats suggest a rapid transition toward profitability. The primary headwinds are technical bearishness and negative insider sentiment, which contrast with the strong fundamental growth trajectory.
Compare Another Pair
Related Comparisons
MRK vs PHAT: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and Phathom Pharmaceuticals, Inc. (PHAT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.